Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsPopular entities in these results
Choose an entity to see the articles in which it was identified.
Matching articles
29,499 articles · page 5 of 2459…cluded 1 150 636 GLP-1 RA users and 1 396 382 DPP-4i users with type 2 diabetes. Weighted baseline characteristics were generally balanced (onl…
…ESCMID Global, 2025) in Vienna, Austria. Granular study data on Herpes Zoster occurrence in adults with haematological malignancies have been…
…icant strain on both Ukrainian and neighbouring health systems. Cancer incidence appeared lower due to delayed detection and migration…
…de (25 936), empagliflozin (715 802), sitagliptin (493 563) and glipizide (832 295) ( online supplemental eTable 1, 5–8). Baseline charac…
…sed risk of various cancers, with a particularly strong link to pancreatic cancer. 1 2 A meta-analysis found that individuals with type 1 diabete…
…e age, duration of T2D, sex, BMI (<30, ≥30 and <35, ≥35 kg/m2), dulaglutide dose, and duration of dulaglutide treatment. The tirzepatide tr…
…d other stakeholders that address SDoH factors impeding optimal diabetes care. Additionally, the wide variety of general SDoH measures a…
…land during the pandemic.36 37 In the years following 2020, the lung cancer diagnoses have increased, but SACT treatment rates have been sl…
… When predicting risks in a general population of patients with chronic kidney disease, for example when identifying patients for referral to renal cl…
…ual infections of seasonal influenza, SARS-CoV-2 infection, and respiratory syncytial virus.61 African vaccine cold chain networks could easily find themse…
…state health sector in which several novel cancer drugs such as osimertinib, alectinib and immunotherapy are not approved for use in advanc…